Schmidlin Thierry, Behiry Enas, Thomas Hannah, Dolton Garry, Marino Fabio, Hasan Samiul, von Essen Magdalena, Gathungu Rose M, Steigenberger Barbara A, Selvadurai Hayden, Dukes Joseph, Brennan Paul E, Spiller Owen B, Silk Jonathan D, Sewell Andrew K, Ternette Nicola
Institute of Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; Research Center for Immunotherapy (FZI), University Medical Center of the Johannes-Gutenberg University, Mainz, Germany; Nuffield Department of Medicine, Centre for Immuno-Oncology, Oxford OX3 7DQ, UK.
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, UK.
Cell Rep Methods. 2025 Aug 18;5(8):101120. doi: 10.1016/j.crmeth.2025.101120. Epub 2025 Aug 4.
Major histocompatibility complex class I-related protein 1 (MR1) plays a central role in the immune recognition of infected cells and can mediate T cell detection of cancer. Knowledge of the nature of the ligands presented by MR1 is still sparse and has been limited by a lack of efficient approaches for MR1 ligand discovery. Here, we present a cross-linking strategy to investigate Schiff base-bound MR1 ligands. Our methodology employs reductive amination to stabilize the labile Schiff base bond between MR1 and its ligand, allowing for the detection of ligands as covalent MR1 adducts by mass spectrometry-based proteomics. We apply our approach to identifying vitamin B6 vitamers pyridoxal and pyridoxal 5'-phosphate (PLP) as MR1 ligands and show that both compounds are recognized by T cells expressing either A-F7, a mucosal-associated invariant T (MAIT) cell T cell receptor (TCR), or MC.7.G5, an MR1-restricted TCR reported to recognize cancer cells, highlighting them as immunogenic MR1 ligands.
主要组织相容性复合体I类相关蛋白1(MR1)在感染细胞的免疫识别中起核心作用,并且可以介导T细胞对癌症的检测。关于MR1所呈递配体性质的了解仍然很少,并且由于缺乏用于发现MR1配体的有效方法而受到限制。在这里,我们提出一种交联策略来研究席夫碱结合的MR1配体。我们的方法采用还原胺化来稳定MR1与其配体之间不稳定的席夫碱键,从而通过基于质谱的蛋白质组学将配体检测为共价MR1加合物。我们应用我们的方法鉴定出维生素B6的维生素形式吡哆醛和5'-磷酸吡哆醛(PLP)作为MR1配体,并表明这两种化合物都被表达A-F7(一种黏膜相关恒定T(MAIT)细胞T细胞受体(TCR))或MC.7.G5(一种据报道可识别癌细胞的MR1限制性TCR)的T细胞所识别,突出了它们作为免疫原性MR1配体的特性。